Cortexyme Revenue and Competitors
Estimated Revenue & Valuation
- Cortexyme's estimated annual revenue is currently $10.2M per year.
- Cortexyme's estimated revenue per employee is $538,421
- Cortexyme's total funding is $225M.
- Cortexyme's current valuation is $319.1M. (January 2022)
Employee Data
- Cortexyme has 19 Employees.
- Cortexyme grew their employee count by -37% last year.
Cortexyme Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Cortexyme?
Cortexyme is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimerￃﾢ￢ﾂﾬ￢ﾄﾢs and other degenerative diseases. Cortexyme is targeting a specific pathogen found in the brain of Alzheimerￃﾢ￢ﾂﾬ￢ﾄﾢs patients that causes neurodegeneration and other pathology in animal models. Cortexymeￃﾢ￢ﾂﾬ￢ﾄﾢs lead small molecule, atuzaginstat (COR388), has advanced through Phase Ib and is currently the subject of a Phase 2/3 GAIN clinical trial in mild to moderate Alzheimerￃﾢ￢ﾂﾬ￢ﾄﾢs disease patients.
keywords:N/A
$225M
Total Funding
19
Number of Employees
$10.2M
Revenue (est)
-37%
Employee Growth %
$319.1M
Valuation
N/A
Accelerator
Cortexyme's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EVP Research and Development | Reveal Email/Phone |
2 | VP, Human Resources | Reveal Email/Phone |
3 | Director Information Technology | Reveal Email/Phone |
4 | VP, Corporate Communications & IR | Reveal Email/Phone |
Cortexyme News
Cortexyme Inc (CRTX) stock has fallen 19.92% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.
Cortexyme (NASDAQ:CRTX) Downgraded to Sell at Zacks Investment Research. Posted by admin on Apr 19th, 2022. Share on Twitter Share on Facebook Share on...
Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, Koppers, RBB, and SelectQuote and Encourages Investors to Contact the Firm.
The company is developing COR388, an orally administered bacterial protease inhibitor that targets an antigen in the brains of Alzheimer’s patients that Cortexyme co-founder and Chief Scientific Officer Stephen Dominy discovered. COR388 is designed to inhibit the pathogen in a way that broad-spe ...
Cortexyme, Inc., a South San Francisco, CA-based clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s disease (AD) and other degenerative diseases, completed a $76m Series B financing. Backers included new investors Sequoia Capital, Vulcan Capital, Ve ...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.4M | 19 | 12% | $100M |
#2 | $0.6M | 19 | -10% | $88.5M |
#3 | $0.6M | 19 | 73% | $331.5M |
#4 | $1.7M | 19 | N/A | N/A |
#5 | $1.6M | 19 | N/A | N/A |